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How cell death shapes cancer
V Labi*,1 and M Erlacher2,3
Apoptosis has been established as a mechanism of anti-cancer defense. Members of the BCL-2 family are critical mediators of
apoptotic cell death in health and disease, often found to be deregulated in cancer and believed to lead to the survival of malignant
clones. However, over the years, a number of studies pointed out that a model in which cell death resistance unambiguously acts
as a barrier against malignant disease might be too simple. This is based on paradoxical observations made in tumor patients as
well as mouse models indicating that apoptosis can indeed drive tumor formation, at least under certain circumstances. One
possible explanation for this phenomenon is that apoptosis can promote proliferation critically needed to compensate for cell loss,
for example, upon therapy, and to restore tissue homeostasis. However, this, at the same time, can promote tumor development by
allowing expansion of selected clones. Usually, tissue resident stem/progenitor cells are a major source for repopulation, some of
them potentially carrying (age-, injury- or therapy-induced) genetic aberrations deleterious for the host. Thereby, apoptosis might
drive genomic instability by facilitating the emergence of pathologic clones during phases of proliferation and subsequent
replication stress-associated DNA damage. Tumorigenesis initiated by repeated cell attrition and repopulation, as confirmed in
different genetic models, has parallels in human cancers, exemplified in therapy-induced secondary malignancies and
myelodysplastic syndromes in patients with congenital bone marrow failure syndromes. Here, we aim to review evidence in
support of the oncogenic role of stress-induced apoptosis.
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Facts
 During cancer development, clonal selection is facilitated by
the acquisition of mutations in oncogenes and tumor
suppressors and by the selection of 'winner' cells.
 Apoptosis of (pre)-cancerous cells generates vacant niches
that potentially become repopulated by more aggressive
sub-clones. Thereby, apoptosis increases proliferative
pressure and promotes clonal selection, thus driving tumor
evolution.
 Dying cells can promote cell division of neighboring
cells.
Open Questions
 Does apoptosis drive malignant transformation in pre-
malignant conditions such as therapy-related myelodys-
plastic syndromes or congenital bone marrow failure
syndromes?
 Can resistance to apoptosis delay the risk of (further)
malignant transformation within fully established tumors or
in pre-malignant tissues?
 How can unnecessary tissue damage and inflammatory
response be avoided in tumor patients as well as in patients
presenting with premalignant conditions?
Two concepts in the field of tumorigenesis are widely
accepted. First, cancer is the result of sequential genetic
changes that, eventually, transform normal into malignant
cells, a model that has been referred to as multistep
carcinogenesis.1 Second, specific biological processes have
to be deregulated during tumor evolution to enable and sustain
tumorigenesis. These processes have been summarized as
'hallmarks of cancer' by Hanahan and Weinberg2 in the years
2000 and 2011, respectively, and among those, evasion from
cell death is still regarded as an essential mechanism required
for malignant transformation and tumor maintenance.
Though every dogma has its day, doubt is the driving force
behind scientific progress. In this review, we challenge the
current paradigmatic view that increased survival is unam-
biguously promoting tumorigenesis. Wewill discuss the role of
apoptosis and its deregulation during the induction, progres-
sion and maintenance of malignant disease. Finally, we
propose to adopt the current view that resistance to cell death
constitutes a genuine hallmark of cancer, as we believe that
this may actually be limited to certain settings.
Apoptosis deregulation in cancer
Though cells can commit suicide by multiple ways, most cell
death in vertebrates is mediated by the mitochondrial
(intrinsic) pathway that is initiated by a plethora of signals,
1Max-Delbrück-Center for Molecular Medicine (MDC), Berlin 13125, Germany; 2Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and
Oncology, University Medical Center of Freiburg, Freiburg 79106, Germany and 3Freiburg Institute for Advanced Studies, University of Freiburg, Freiburg 79104, Germany
*Corresponding author: V Labi, Immune Regulation and Cancer, Max-Delbrück-Center for Molecular Medicine, Robert Ro ̈ssle-Strasse 10, 13125 Berlin, Germany.
Tel: +49 30 9406 3462; Fax: +49 30 9406 2390; E-mail: verena.labi@mdc-berlin.de
Received 05.12.14; revised 28.12.14; accepted 02.1.15; Edited by G Melino
Abbreviations: BH3-only, BCL-2 homology domain 3-only; HCC, hepatocellular carcinoma; HSC, hematopoietic stem cell; MDS, myelodysplastic syndrome; MDR-AML,
MDS-related acute myeloid leukemia; RA, refractory anemia; RAEB, RA with excess blasts; RAEB-T, RAEB in transformation
Citation: Cell Death and Disease (2015) 6, e1675; doi:10.1038/cddis.2015.20
& 2015 Macmillan Publishers Limited All rights reserved 2041-4889/15
www.nature.com/cddis
such as DNA damage, growth factor deprivation, develop-
mental cues as well as many standard anti-cancer therapies.
The initiators of this pathway belong to the BCL-2 family
(Figure 1) and the balance between anti- and pro-apoptotic
family members, the so-called 'Bcl-2 rheostat' determines
whether a cell will live or die an apoptotic death.
On the basis of the 'hallmarks of cancer' concept mentioned
above, Green and Evan3 proposed that the core changes
converting a normal cell into a malignant one might be simply
increased proliferation coupled to decreased cell death.
Indeed, it is fully established that tumor cells dampen the
apoptotic response, as only defective death prevents their
effective elimination by intrinsic anti-cancer mechanisms or
anti-cancer therapy.4
Progressive counteraction of pro-death signals is a con-
sequence of exogenous aswell as (epi)genetic changes in the
rich set of factors regulating apoptosis. Though mutations in
genes encoding for core components of the cell-death
machinery, for example, BCL-2 family proteins, are described
in literature, they are not particularly common. One prominent
exception occurs in B-cell follicular lymphoma where fusions
between BCL-2 and the immunoglobulin heavy chain gene are
regularly detected thus raising BCL-2 protein levels.5–7 More
commonly, upstream signaling pathways converging at the
level of the BCL-2 family are deregulated within tumor cells
secondarily leading to an imbalance in the BCL-2 rheostat
tilting the balance in favor of survival.
The tumor suppressor gene TP53 is frequently mutated in
human cancer and has early been linked to apoptosis.8–10
Activated upon DNA damage, hypoxia or oncogene activation,
TP53 initiates cell cycle arrest and DNA repair or, in
irreversibly damaged cells, senescence or apoptosis, with
PUMA and NOXA being the main pro-apoptotic target
genes.11–15 Loss-of-function mutations in TP53 result in
apoptosis resistance and are frequently associated with
advanced tumor stage and poor prognosis.16,17 Besides
TP53, other components of the DNA damage checkpoint
pathway are frequently inactivated in human cancer (e.g.,
MDM2, ARF, RB1).18,19 Common mutations in oncogenes
causing their growth factor-independent activation can be
found in the RAS-signaling pathway, such as mutations in the
RAS genes itself (i.e., HRAS, NRAS, KRAS) or upstream/
downstream components of growth factor signaling pathways
(e.g., FLT3, CKIT, EGFR, PTPN11, CBL, NF1 etc.).20 The
main BCL-2 players repressed downstream of these pathways
are PUMA, BAD and BIM, BH3-only proteins that are kept
inactive by AKT signaling.21,22 In colorectal cancers, the
adaptor protein paxillin has been reported to promote survival
and chemo-resistance of tumor cells by increasing BCL-2
protein stability and abundance.23 The c-MYC-oncogene can
induce tumors in its wild-type form and is overexpressed in
most human tumor entities.24 Paradoxically, at high levels it
promotes apoptosis involving BCL-2 family proteins. Many
other mutated oncogenes or tumor suppressors have been
described to deregulate intrinsic apoptosis signaling but
detailed information on their main downstream apoptotic
effectors is often lacking.
Besides cell-intrinsic pro-survival signals, support from the
environment is critically required for tumor cell survival. For
example, chronic lymphocytic leukemia cells survive well in a
Figure 1 Cytotoxic agents impact the Bcl-2 rheostat. The pro- and anti-apoptotic BCL-2 family proteins closely interact at the mitochondrial membrane and regulate the
intrinsic apoptosis pathway. Cellular stress causes activation of pro-apoptotic BCL-2 proteins from the BH3-only sub-group (BIM, PUMA etc.). These bind to and inhibit their anti-
apoptotic antagonists (BCL-2, MCL-1 etc.), thus releasing and activating the downstream effectors BAK and BAX. Mitochondrial membrane permeabilization (MOMP) is
triggered, and pro-apoptotic molecules released into the cytoplasm activate caspases (in more detail reviewed by Labi et al.120). Conventional cytotoxic agents interfere with
upstream signaling pathways converging at the BCL-2 family level. In contrast, BH3-mimetics directly inhibit pro-survival BCL-2 proteins
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lymph-node niche in vivo but rapidly undergo apoptosis
ex vivo. This indicates that (i) the downstream apoptosis
machinery is usually functional in these cells, and, that (ii) they
are ready-to-die and as such strictly dependent on niche-
derived pro-survival signals.25 Indeed, high levels of the BH3-
only proteins BIM, BMF and NOXA were detected in primary
human chronic lymphocytic leukemia cells.26–29 Co-culture
with feeder or T-helper cells as well as addition of cytokines
strongly delays ex vivo apoptosis by increasing expression of
anti-apoptotic BCL-2 proteins.25,30,31
BCL-2 proteins as targets for anti-cancer therapies
Although resistance to cell death is an important feature of
cancers, it is certainly not true that tumors are fully resistant to
cell death.32 If true, anti-cancer therapies would invariably fail.
The majority of today’s therapeutic regimens aim to directly kill
tumor cells and often successfully reduces tumor mass.
Depending on the treatment scheme, different but often
overlapping pathways are engaged leading to apoptosis
and/or necrosis (i.e., DNA damage, oxidative or metabolic
stress, and others). Not unexpectedly, clinical trials use the
amount of treatment-induced cell death within tumors to predict
prognosis and decide on further treatment intensity (i.e., steroid-
response in pediatric acute lymphoblastic leukemia).33
Most conventional cytotoxic agents act by activating the
intrinsic apoptosis pathway (Figure 1). DNA damaging agents
(i.e., etoposide or alkylating agents) as well as γ-irradiation
induce apoptosis by TP53-mediated activation of PUMA and
possibly also NOXA.12,13 In contrast, steroids kill acute
lymphoblastic leukemia cells by activation of BIM, PUMA
and/or BMF,34 and imatinib has been shown to kill BCR-ABL-
positive chronic lymphocytic leukemia cells in a BIM- and
BAD-dependent manner.35 Alternatively, apoptosis suscept-
ibility of chronic lymphocytic leukemia cells can be increased
by the CXCR4 antagonist plerixafor because of mobilization-
dependent loss of survival signals in lymph-node niches.25,36
Thereby, pro-survival signals within tumor cells drop and the
BCL-2 rheostat favors induction of apoptosis.
Recently, specific compounds that induce apoptosis directly
at the BCL-2 level have been developed (Figure 1). These
'BH3-mimetics' (i.e., ABT-737, ABT-263, ABT-199 and Obato-
clax) mimic BH3-activity by binding and inhibiting pro-survival
BCL-2 proteins.37 They hold big promise for anti-cancer
therapy, either alone or in combination with other modalities.
Among all pro-survival BCL-2 proteins, only BCL-2, BCL-xL
and BCL-W are bound with relevant affinities by ABT-737
and ABT-263.38,39 Accordingly, resistance of tumor cells
is commonly caused by high levels of MCL-1 and/or
BFL1/A140 and thus targeting these two proteins has become
increasingly interesting.
The apoptosis paradox in tumor development
Complete apoptosis resistance coupled with unleashed
proliferation would make any tumor grow to a mass of
unbearable size in a very short period of time, a fact
inconsistent with the usually long latency of malignant
disease. An uncontrollably proliferating cell has to undergo
only 40 population doublings until a clinically detectable tumor
mass comprising approximately 109 cells appears. This lesion
would require only 10 further doublings to produce 1012 cells, the
maximal tumor size compatible with human life.41 As such rapid
growth is rare, evolving tumors must be characterized by a
dynamic interplay between proliferation, cell death and/or
senescence. This feature contributes to intra-clonal hetero-
geneity of tumors that consist of subpopulations of cells displaying
variable rates of death, division and aggressiveness.42,43
As discussed earlier, fully transformed cells might have
acquired mutations increasing cell death thresholds and
inhibiting their clearance.44 But how do apoptosis and
acquired apoptosis-resistance actually impact on the process
of malignant transformation? Is apoptosis resistance sufficient
to transform a cell? When and why do transforming or
transformed cells require mechanisms to evade apoptosis?
And, are there situations where apoptosis resistance rather
reduces the risk of (further) malignant transformation?
The involvement of BCL-2 itself in neoplastic transformation
was nailed in 1985 when a translocation juxtaposing the
BCL-2 gene and the immunoglobulin heavy chain gene
t(14;18) was regularly found in human follicular
lymphoma.5–7 This was the first evidence that some
oncogenes rather promote cell survival than stimulate
proliferation. Only later we learned that apoptosis inhibition
per se is hardly ever sufficient to transform a cell, in line with
the above-mentioned multi-step carcinogenesis model.
BCL-2 transgenic mice develop tumors only at low pene-
trance and with long latency,45 and only a fraction of all
persons harboring the t(14;18) translocation in blood cells
subsequently develop follicular lymphoma, and only after a
long-lasting latency period.46
The tumorigenic potential of BCL-2 becomes only evident
when overexpressed in combination with oncogenes such as
c-MYC. Though promoting unleashed proliferation, c-MYC
can only efficiently immortalize cells in the presence of
sufficient pro-survival signals such as those provided by
overexpression of BCL-2.47,48 This need arises because high
levels of c-MYC drive cell death. Thus, apoptosis is an
important barrier to uncontrolled proliferation and a form of
tumor surveillance curtailing MYC-driven transformation.
Consequent studies demonstrated that c-MYC synergizes
with any of the anti-apoptotic BCL-2 proteins in transforming
leukocytes in overexpression models in vivo,49 whereas the
dependence appears more selective at the level of endogen-
ous pro-survival proteins.50 Consistently, the loss of various
pro-apoptotic BH3-only proteins results in acceleration
of c-MYC-driven lymphomagenesis.51–53 Similar synergies
between c-MYC and anti-apoptotic BCL-2 proteins have been
observed in other tissues such as the pancreas or the
mammary gland.54,55 Furthermore, apoptosis is not only
induced by c-MYC overexpression but also by activity-gain
of other oncogenes or the loss of tumor suppressors.
However, this is beyond the scope of this review and was
discussed elsewhere.4,56
Surprisingly, ample data from human tumors and mouse
models actually indicate that the 'simple' view on apoptosis
being a key mechanism of anti-cancer defense suffers from
oversimplification. Studies on human tumors paradoxically
pointed out a strong correlation between high BCL-2 levels
and favorable prognosis (Table 1). These observations
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indicate that BCL-2 overexpression is routinely observed in
human tumors and that it can be associated with a less
aggressive disease course. Along that line, the increased
expression of pro-apoptotic BAX has been correlated with an
increased risk of relapse in childhood acute lymphoblastic
leukemia.57 Gurova et al.58 demonstrated that clonal expan-
sion of transformed TP53-deficient fibroblasts in vitro and in a
mouse tumor model was suppressed by BCL-2 overexpres-
sion. Intriguingly, BCL-2-overexpressing tumors contained
genetically stable cells and were able to restrict the expansion
of otherwise rapidly growing and genetically instable TP53-
deficient cells. In another study, BAX overexpression in the
T-cell lineage enhanced lymphomagenesis in TP53-deficient
mice in a dose-dependent manner, and even initiated
lymphoma formation on a TP53-proficient background.59
In accordance with data discussed before, BAX-driven
apoptosis led to increased chromosome instability, and co-
expression of BCL-2 was able to delay lymphomagenesis.
In sum, these results support a hypothesis in which a higher
rate of apoptosis within a tumor, either at early stage or during
progression, or both, might promote genetic instability causing
more aggressive disease.
A farewell from the classic view on the role of apoptosis
in cancer
How could apoptosis promote tumorigenesis? Cancer deve-
lopment can be viewed as a Darwinistic process of somatic
Table 1 In various tumors, high BCL-2 levels correlate with good prognosis
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cell evolution, whereby initially 'healthy' cells acquire multiple
(epi)genetic lesions driving clonal selection. This process is
facilitated by the acquisition of mutations in oncogenes and
tumor suppressors and by the selection for cells with superior
fitness. Under continuous selection pressure, apoptosis could
be a major driver of clonal expansion by generating vacant
niches (Figure 2). These niches become repopulated by more
aggressive sub-clones with certain competitive advantages. In
that respect, apoptosis would be a driver of tumor evolution
and a hallmark of aggressive disease. This could be especially
relevant during early steps of tumorigenesis. Pre-malignant
lesions can stably persist for an extended period of time while
still too small to be clinically relevant.
Proof-of-principle experiments exploring cell competition
and compensatory proliferation in D. melanogaster larval
development suggest a dual role for apoptosis during early
tumorigenesis with the need to dampen intrinsic pro-apoptotic
signals to promote tumor cell survival on one hand, and the
benefit from the death of surrounding cells on the other
hand.60,61 This can be described as a type of Darwinian-like
selection that generates 'winner' and 'loser' cells thus leading
to long-term outgrowth of certain cells over others. In
particular, preventing apoptosis of surrounding wild-type cells
impairs the growth of otherwise highly proliferating clones,
both in the cases of DMYC-induced super-competition60 and
Minute-induced cell-competition.61 It has only recently been
shown that this competition relies on TOLL signaling inducing
NFκB-dependent apoptosis in 'loser' cells and their subse-
quent engulfment by 'winner' cells.62,63
Along this line, a natural cell competition has been
described for thymic progenitor cells in the mouse. Young
cells recently immigrated from bone marrow displace 'older'
progenitors already residing in the thymus. The 'older', 'loser'
cells, express lower BCL-2 levels and are more susceptible to
apoptosis. Consequently, reduction of natural competition in
healthy thymic tissue causes T-cell lymphoma.64,65
Mathematical models allow for an approximation of how
intrinsic cell properties influence growth dynamics and clonal
expansion.66,67 Enderling et al.68 predict that spontaneous cell
death yields a tumor size reduction in the short term, but
ultimately enhances tumorigenesis in the long term. They
conclude that tumors can remain dormant for long intervals
despite constant cellular turnover and that high apoptosis
rates perturb the intrinsic tumor dynamics and shift the
population towards more aggressive subclones.69 Wodarz
et al.70 describe the relation between death rate and the
Figure 2 How apoptosis shapes cancer. (a) In proliferative tissues, injury is followed by rapid regeneration and restoration of normally sized and shaped structures. In the
Drosophila wing imaginal disc, apoptotic cells induce competitive proliferation by secretion of mitogenic factors in a caspase-dependent manner. (b) In tissues with aberrant cells,
tissue injury (e.g. caused by DNA damage in MDS patients) and consecutive proliferation enables outgrowth of more aggressive clones. This fosters malignant transformation.
(c) Within established tumors, chemo- or radiotherapy induces apoptosis but leads to death-induced proliferation of therapy-surviving cells. Following the generation of space,
proliferation is mediated by mitogens derived from apoptotic cells (such as PGE2). As proposed in mathematical models, this results in increased sub-clonal variability with a
higher risk of tumor progression, chemoresistance and relapse
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generation of mutant cells within a population after a first wave
of clonal expansion. In their mathematical model, they find that
less cell death correlates with fewer cell divisions during clonal
expansion, thus leading to a less variable cell population. In
contrast, high death rates correlate with more cell divisions
during expansion causing the appearance of many different
mutants (Figure 2). With increasing sub-clonal variability, the
risk that individual cells overcome selective barriers (i.e.
growth inhibition) and progress towards malignancy
increases.70 We are putting forward the question whether
these in silico models on cell death-stimulated tumor progres-
sion find their counterparts in vivo.
Death-driven proliferation facilitates tissue regeneration
and tumorigenesis
One piece of evidence in favor of these mathematical models
comes from two studies on thymic T-cell lymphoma where
genetic ablation of the pro-apoptotic BH3-only protein
PUMA abolished tumor formation.71,72 In this mouse model,
lymphomagenesis is induced by repeated rounds of sub-lethal
γ-irradiation and strongly accelerated by TP53 deficiency.73
Repeated γ-irradiation induces amassive wave of apoptosis in
the hematopoietic compartment that is dependent on the
TP53 target, PUMA.13 Initially, these studies aimed at
confirming the tumor suppressor potential of PUMA, as was
suggested by the fact that its loss accelerated MYC-induced
lymphomagenesis.53,74 Unexpectedly, PUMA deficiency
protected mice efficiently from thymic lymphoma. Why does
deletion of PUMA abrogate lymphoma formation whereas
loss of its activator, TP53, does the opposite? Two studies on
the competition of hematopoietic progenitors shed light on
possibly underlying mechanisms. Hematopoietic stem cells
(HSCs) carrying damaged DNA introduced by sub-lethal
irradiation can effectively reconstitute myelo-ablated mice.
However, they are outcompeted when transplanted in
a competitive setting with TP53-deficient HSCs.75,76
As transplantation of lethally irradiated recipients requires
HSC expansion for hematopoietic regeneration, it is tempt-
ing to speculate that selective pressure during repopulation
provides the basis for oncogenic mutations to appear. This
theory is backed up by a study using tamoxifen-induced
TP53 expression on a TP53-deficient genetic background.
When TP53 expression was limited to the time of irradiation,
DNA damage led to strong apoptosis of hematopoietic cells
and subsequently to cancer development. In contrast, when
TP53 expression was only allowed at later time points, no
apoptosis was induced by irradiation but also no cancer
manifested. Thus, the tumor-preventive function of TP53 is
not critical during the acute elimination of damaged cells but
rather essential at later time points when cells that survived
irradiation despite carrying genetic aberrations drive tumor
progression.77
The observations in PUMA-deficient mice are consistent
with these results and suggest that TP53-dependent apopto-
sis triggered during an acute DNA damage response is not
only irrelevant for tumorigenesis, but even promotes lym-
phoma formation. This is underlined by the finding that
resistance to radiation-induced lymphoma in PUMA-deficient
mice can be overcome by PUMA-independent apoptosis
induction, that is, by glucocorticoid treatment upon
irradiation.72 The tumor-initiating cells in this tumor model
are hematopoietic stem or progenitor cells, because T-cell
specific overexpression of pro-survival Bcl-xL failed to prevent
irradiation-induced lymphomagenesis despite protecting thy-
mocytes and peripheral T cells from death whereas mice
overexpressing BCL2 throughout hematopoiesis phenocop-
ied PUMA-deficient mice.71,72 Strikingly, in wild-type mice,
persisting PUMA- and TP53-dependent apoptosis is still
detected 1 week after irradiation specifically in hematopoietic
progenitors as compared with more differentiated cells
indicating excessive pressure within the proliferating progeni-
tor compartment to compensate for the cell loss.78
The association between death-driven proliferation and
cancer is best established in mouse models of hepatocellular
carcinoma (HCC). In humans, HCC almost invariably devel-
ops in the context of chronic liver inflammation that is linked to
tissue injury and cell death caused by viral hepatitis, chronic
alcohol consumption, excessive hepatosteatosis or environ-
mental toxins.79 The regenerative response is accompanied
by a release of pro-inflammatory factors by dying hepatocytes
and subsequent expansion of un-differentiated precursors
such as tissue stem cells. Given the strong impact of apoptosis
on HCC development, Qiu et al.80 investigated the role of
PUMA in a mouse model of carcinogen-induced liver cancer.
They found that PUMA was activated by JNK1 and critically
mediated carcinogen-treatment-induced apoptosis. Impor-
tantly, PUMA deficiency decreased the multiplicity and size
of emerging tumors.81 Two further studies could show that
liver-specific Mcl-1 deletion induced spontaneous hepatocyte
apoptosis, chronic proliferation and finally caused HCC.
Noteworthy, in this mouse model, HCC developed in the
absence of carcinogen treatment or detectable inflammation
and hepatocytes of HCC-like lesions showed a high degree in
genomic instability.82,83
Mechanisms coupling cell death and proliferation
The discussed mouse models indicate that apoptotic cells
promote cell divisions of neighboring cells, a process that can
be termed death-driven proliferation, but the underlying
signaling events remain elusive.84 Only recently, evidence
has emerged howapoptotic cells can promote the proliferation
of surrounding cells. Planarians regenerate complete indivi-
duals from the smallest of body parts upon injury85 by a
process termed compensatory proliferation.86,87 Apoptosis
mediated by pro-death effectors like the caspase-like gene 3
(DjCLg3) is not restricted to the wound but occurs in primarily
unaffected tissue and is thus actively involved in driving full
restoration of body pieces.88 In Hydra, head regeneration after
amputation requires secretion of Wnt3 by dying cells, thus
initiating β-catenin-driven proliferation of surrounding cells.
Blocking apoptosis by caspase inhibitors prevents head
regeneration and can be overcome by exogenous Wnt3.89 In
theDrosophila wing imaginal disc, a highly proliferative tissue,
radiation-induced apoptosis is followed by rapid tissue
regeneration to form adult structures of normal size and
shape (Figure 2). Mechanistically, activity of the initiator-
caspase Dronc in apoptotic cells promotes JNK and Wingless
signaling pathways, thus causing the secretion of mitogens
The paradox of cell death driven cancers
V Labi and M Erlacher
6
Cell Death and Disease
Decapentaplegic (Dpp) and Wingless (Wg) to promote tissue
regeneration.90–92 Keeping apoptosis-initiated cells artificially
alive by inhibiting downstream effector caspases prevented
injury-induced death. Persistence of such 'undead' cells
resulted in excessive proliferation and hyperplastic overgrowth
due to continuous and inappropriate secretion of mitogens. In
contrast to proliferating tissues where Dronc-initiated apopto-
sis induced Dpp and Wg expression, apoptosis-induced
proliferation in committed non-dividing photoreceptor neurons
in Drosophila larvae required activity of the effector caspases
DrICE and Dcp-1, which subsequently force cell cycle entry
mediated by Hedgehog (Hh) signaling.93
Extrapolating to human tumors, the ability of apoptotic cells to
actively promote proliferation of surrounding cells, for example
by secreting mitogens, might be of major significance. We
speculate that cell–cell communication likely couples prolifera-
tion and cell death either passively or through signals actively
elicited by apoptotic cells. In support of the latter, a recent study
in xenotransplanted mice suggests that dying cells directly
induce proliferation of neighboring cells. Upon radiotherapy-
induced tumor cell apoptosis, caspase-3 activity led to the
activation of iPLA2 and subsequent release of prostaglandin E2
by apoptotic tumor cells and neighboring stroma. Prostaglandin
E2 in turn served as promoter of tumor cell survival and
proliferation.94 In this model, the net response to therapy was
determined by radiation-induced tumor cell apoptosis and
prostaglandin E2-driven cell survival and proliferation.
An additional layer of communication between dying and
proliferating cells is provided by immune and inflammatory cells.
Dying cells activate macrophages, dendritic cells, neutrophils
andmast cells that secretemitogenic cytokines such as IL1, IL6
or TNFα.95 Thus, next to their major function of immune
surveillance,96 the immune and inflammatory systems also
foster malignant transformation under certain circumstances.95
In sum, we propose that understanding the impact of death-
driven proliferation on tumorigenesis, either directly or mediated
by inflammatory signals, can open a new avenue to improve
therapy and potentially prevent cancer development.
From animal models to human disease
The animal models discussed earlier indicate that too much
apoptosis compromises healthy or premalignant tissues by
increasing proliferative pressure and clonal selection fostering
outgrowth of malignant clones. But do these observations
reflect tumorigenesis as it occurs in humans? And if yes, which
tissues and cancer types could be affected?
The concept of apoptosis-driven cancer can be applied to
therapy-induced secondary tumors that originate from distinct
tissues than the primary tumors. These tumors arise as a
consequence of genomic instability97 likely provoked by
repeated cycles of excessive apoptosis and subsequent
proliferation during therapy. Typically, they compromise
tissues with high regenerative capacity (i.e., breast, intestine,
rectum, skin or thyroid gland) and frequently present in the
area of previous irradiation.
Adult survivors of childhood cancer have a sixfold increased
risk to develop secondary tumors later in life.98 This is either
due to underlying genetic (e.g., germline mutations in cancer
susceptibility genes99) and/or environmental factors (e.g.,
nicotine abuse) that predispose these patients to tumors or to
previous therapies including chemotherapy or irradiation.
Patients who suffer from a combination of an underlying
genetic predisposition and earlier application of chemotherapy
or radiation therapy have an excessively high risk to develop
secondary tumors.100
Bone marrow, a radiosensitive tissue,101 frequently gives
rise to secondary malignancies as suggested by the
above-described mouse model of irradiation-induced
lymphomagenesis.71,72 However, thymic lymphomas are rare
in humans and do not occur as therapy-inducedmalignancies.
In contrast, in humans, exposure to radio- or chemotherapy
rather increases the risk to develop therapy-related myelo-
dysplastic syndromes (MDS).102
MDS are clonal malignancies originating from defective
bone-marrow-derived HSCs, in which critical driver mutations
provide them with a selective advantage (Figure 3). This
disease is characterized by ineffective hematopoiesis causing
Figure 3 The rise and fall of apoptosis during MDS pathogenesis. Therapy-related myelodysplastic syndrom (MDS) is caused by repeated cycles of radio- or
chemoradiotherapy (i.e., including alkylating agents) that lead to bone marrow attrition and subsequent regeneration. In children and adolescents, MDS can develop on the basis
of congenital bone marrow failure syndrome such as Fanconi anemia and Dyskeratosis congenita. MDS frequently progresses to MDS-related AML (MDR-AML). The stepwise
evolution of MDS is reflected by the FAB classification, which distinguishes between refractory anemia (RA), RA with excess blasts (RAEB), RAEB in transformation (RAEB-T)
and MDR-AML
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peripheral cytopenia(s) and bone marrow dysplasia. Abnor-
mal clonal progenitor cell differentiation and increased
susceptibility of immature progenitors to apoptosis underlie
these symptoms. The risk to develop MDS increaseswith age,
suggesting that accumulation of genetic damage influences
pathogenesis. Exposure to alkylating agents, chemo- or radio-
therapy of cancer patients dramatically increases the risk to
develop therapy-related MDS (lifetime risk of 2–10%).102
MDS has a high propensity to progress to MDS-related AML
(MDR-AML). Disease progression is characterized by an
increased percentage of bone marrow blast cells and
cytogenetic abnormalities (reviewed by Corey et al.102).
In analogy to therapy-related MDS of adults, children and
adolescents can develop secondary MDS and MDR-AML on
the basis of congenital bone marrow failure syndromes
(Figure 3). These syndromes are caused by gene mutations
affecting diverse cellular pathways but all resulting in
premature failure of hematopoiesis. In individuals with
these congenital conditions, HSCs become prematurely
exhausted and are excessively susceptible to apoptosis or
senescence.103 The most frequent bone marrow failure
syndromes are Fanconi anemia, caused by mutations in
DNA repair genes, and dyskeratosis congenita, characterized
by premature telomere shortening.103,104 Fanconi anemia and
dyskeratosis congenita have an inherent risk to transform
into MDS, with prevalence of 30–40% and 10–15%,
respectively.105 Additionally, patients with these syndromes
are at risk to develop other malignancies, with those children
having the highest risk that previously were subjected to
chemotherapeutic agents or irradiation.105
Both, therapy-related and secondary MDS are caused by
cumulative HSC injury via DNA damage or oxidative stress. In
patients with or animal models of bone marrow failure
syndromes and low-risk MDS, HSCs are exceptionally suscep-
tible to apoptosis.106–108 This indicates that, in line with the
aforementioned animal models, excessive apoptosis generates
vacant cell compartments that subsequently are repopulated by
more competitive HSCs. Proliferative pressure is further
increased by peripheral cytopenias and feedback loops to the
bone marrow. Thus, apoptosis might be a major driver of
disease progression during early stages of MDS and final
transformation to full-blown AML. The pathophysiology of
Fanconi anemia, dyskeratosis congenita and therapy-related
MDS suggests that chronic HSC apoptosis can be attributed, at
least in part, to chronic DNA damage checkpoint signaling, with
ATM/ATR, CHK1, CHK2 and TP53 being central players.109
These checkpoints preserve genetic stability and act as a barrier
to malignant transformation,110 thus evolving tumor cells are in
need to inactivate them. Accordingly, the amount of apoptotic
CD34+HSCs gradually decreases during further progression to
MDR-AML. The pressure to inactivate DNA damage checkpoint
signaling is reflected by the fact that therapy-related AML more
frequently harbor TP53 mutations than AML developing de
novo111 and that clones harboring TP53mutations are selected
during malignant transformation of therapy-related AML.112
Similarly, CHK1 and CHK2 are strongly activated in MDS, but
almost completely inactivated in MDR-AML cells.113
We have learned from animal models of bone marrow failure
andMDS aswell as patients’ subgroups that cells with activated
checkpoint signaling display competitive disadvantages.
Accordingly, checkpoint abrogation rescues proliferation and
survival of HSCs, but also increases the risk of malignant
transformation.109,114,115 What if, instead of checkpoint abroga-
tion, apoptosis would be inhibited in early-stage MDS whereas
all other pathways downstream of the DNA damage checkpoint
remain active? On the basis of observations made in the murine
thymic lymphoma model, we would expect an increase in bone
marrow cellularity, thus relaxing proliferative pressure and
delaying further transformation fromMDS toMDR-AML. Indeed,
the first MDS mouse model available supports this concept:
Slape and colleagues116 recently showed that BCL-2 over-
expression in NHD13 mice corrects macrocytic anemia and
delays leukemic transformation. Further mouse models will be
required to elucidate the role of apoptosis susceptibility or
resistance, respectively, for pathogenesis and progression of
bone marrow failure syndromes and MDS to AML.
Perspectives
Moving away from the paradigmatic view prevailing the last
decades, the relationship between cell death and cancer gets
far more complex than originally anticipated. Beyond doubt,
the traditional view that intrinsic death of potentially dangerous
cells is preventive to tumor development still holds true in
many aspects. However, it disregards the fact that cells are
placed in and interact with their environment. At the first
glance, the dual function of apoptosis in tumorigenesis is a
challenging concept, but these conflicting roles are not
incompatible with common beliefs and might also depend on
the tissue and the sequence of events during transformation.
The balance between proliferation, senescence and death
likely adapts during tumor progression. Tumor initiation must
be accompanied by the odd survival of single 'initiated' cells
that carry driver mutations. Recently, light has been shed on
the process of initiation of hematological malignancies. Driver
mutations conferring HSCs with selective advantages (i.e., in
DNMT3A, JAK2, ASXL1, TET2 and others) lead to clonal
expansion in aged individuals, who do not (yet) suffer from
leukemia or MDS.117 During further tumor progression, cancer
cells frequently respond to their altered state by undergoing
programmed cell death and remain highly dependent on
certain survival signals from their environment.118,119 Within a
growing tumor, apoptosis will preferentially eliminate those
sub-clones with the highest apoptosis sensitivity whereas
sparing the more resistant cells. Thus, cell death imposes a
huge selection pressure favoring clonal expansion of more
aggressive sub-clones. Hence, even fully established tumors
are rarely completely resistant to apoptosis, and death
induced by hypoxia or chemotherapeutics increases prolif-
erative pressure and clonal selection paving the way for
therapy-refractory or relapsing cancers.
In light of these findings, it becomes apparent that standard
anti-cancer therapies face a dilemma by aiming at inducing
tumor cell death. Hence, we believe that we are in need for
better treatment strategies to avoid unnecessary tissue
damage and inflammatory responses in tumor patients as
well as in patients presenting with premalignant conditions
such as bone marrow failure or viral hepatitis. We are still only
beginning to understand the complex mechanisms involved in
tumor development and progression, and thus further
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research is necessary to understand the contribution of
apoptosis in shaping tumors, as a prerequisite to generate a
more comprehensive picture on tumorigenesis and allowmore
effective therapeutic intervention.
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